<DOC>
	<DOCNO>NCT00711243</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , oxaliplatin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose docetaxel give oxaliplatin fluorouracil see well work treat patient metastatic unresectable stomach cancer , gastroesophageal junction cancer , solid tumor .</brief_summary>
	<brief_title>Docetaxel , Oxaliplatin , Fluorouracil Treating Patients With Metastatic Unresectable Stomach Cancer , Gastroesophageal Junction Cancer , Other Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum tolerate dose docetaxel administer oxaliplatin fluorouracil patient metastatic unresectable solid tumor . ( Phase I ) - To determine response rate patient metastatic unresectable adenocarcinoma stomach gastroesophageal junction treat regimen . ( Phase II ) Secondary - To determine dose limit toxicity regimen patient . - To evaluate frequency CYP3A4 , CYP3A5 , MDR polymorphisms impact toxicity docetaxel . - To evaluate frequency XRCC1 ERCC2 polymorphisms impact toxicity oxaliplatin . - To evaluate frequency DPD TSER polymorphisms impact toxicity fluorouracil . - To characterize toxicity profile regimen patient . OUTLINE : This dose-escalation study docetaxel . Patients receive docetaxel IV 1 hour oxaliplatin IV 2 hour day 1 fluorouracil IV continuously 46 hour day 1 2 . Treatment repeat every 14 day least 2 course absence disease progression , symptomatic tumor progression , unacceptable toxicity . Patients undergo blood sample collection periodically pharmacokinetic pharmacogenomic correlative study . Plasma concentration docetaxel analyze reverse-phase high performance liquid chromatography tandem mass spectrometry . Polymorphisms CYP3A4/5 , MDR , gene analyze PCR . After completion study therapy , patient follow every 3 month . PROJECTED ACCRUAL : A total 73 patient ( 30 phase I 43 phase II ) accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic surgically unresectable solid tumor meeting 1 follow criterion : Any solid tumor ( Phase I ) Adenocarcinoma stomach gastroesophageal junction ( Phase II ) Unidimensionally measurable disease CT scan MRI No uncontrolled brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 01 ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8.0 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin normal Meets 1 follow criterion : Alkaline phosphatase ( AP ) normal AND AST ALT ≤ 5 time ULN AP ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN AP ≤ 5 time ULN AND AST ALT normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study therapy No preexisting neuropathy No concurrent uncontrolled illness condition would preclude study compliance No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No history allergic reaction attribute compound similar chemical biologic composition agent use study PRIOR CONCURRENT THERAPY : Recovered prior therapy More 4 week since prior therapy ( Phase I ) No prior oxaliplatin taxanes ( Phase I ) More 4 week since prior radiotherapy ( Phase I ) No two prior therapy metastatic disease ( Phase I ) No prior therapy metastatic disease ( Phase II ) At least 6 month since prior adjuvant therapy ( give prior occurrence metastatic disease ) ( Phase II ) Prior fluorouracil concurrent radiotherapy palliation primary tumor allow provide metastatic disease present outside radiotherapy field ( Phase II ) No prior radiotherapy ≥ 30 % bone marrow No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>